Thymosin Alpha-1 — Research Dossier
Evidence grading
Structure
28-amino-acid
Thymic peptide; naturally produced in the thymus
Approved (ex-US)
35+ countries
Zadaxin / thymalfasin; chronic hepatitis B and immune restoration
Human subjects
11,000+
30+ clinical trials across hepatitis, sepsis, and immune indications
US FDA approval
None
Paradox: approved globally but never FDA-approved in the United States
Thymosin Alpha-1 is one of the most extensively clinically tested immunomodulatory peptides in the world — 30+ trials, 11,000+ subjects, 35+ country approvals — and a notable regulatory paradox, being approved across dozens of countries yet never by the US FDA. It is NOT the same compound as Thymosin Beta-4 (TB-500).
Thymosin Alpha-1 (Tα1, thymalfasin; brand Zadaxin) is a 28-amino-acid peptide naturally produced in the thymus, first isolated from thymic tissue in 1972. It is approved in 35+ countries (Italy was first) for chronic hepatitis B, as an immune adjuvant, and for immune restoration in immunocompromised patients. Across 30+ clinical trials involving over 11,000 subjects it has shown a consistent safety profile, yet it has never received FDA approval in the United States.
Naming caveat: Thymosin Alpha-1 and Thymosin Beta-4 (marketed as TB-500) are completely different proteins with different sequences, mechanisms, and approved/studied indications. They belong to different thymosin subfamilies. The shared "thymosin" label has caused confusion in the research community; this dossier covers Tα1 (the approved, thymic immunomodulatory peptide) not the actin-sequestering Tβ4 family.
“Thymosin Alpha-1 modulates immunity through TLR2/TLR9 signalling on dendritic cells, simultaneously enhancing pathogen defence via Th1 activation and promoting immune tolerance via IDO-mediated regulatory T-cell generation — acting as an immune modulator that restores balance rather than a simple stimulant.”
— Dominari A et al., World J Virol 2020
Mechanism
Tα1 modulates immunity primarily through Toll-like receptor signalling — TLR2 and TLR9 — on dendritic cells, simultaneously enhancing pathogen defence via Th1 activation and promoting immune tolerance via IDO-mediated regulatory T-cell generation. It acts as an immune modulator rather than a simple stimulant: the same molecule that enhances antiviral responses in hepatitis also restrains inflammatory overactivation in sepsis.
This bidirectional immune-modulating activity is the rationale for its use across both under-active immune states (chronic viral infections, immunocompromised patients) and over-active inflammatory states (severe sepsis, COVID-19). It is mechanistically distinct from Thymosin Beta-4 (TB-500), which is an actin-sequestering peptide operating through completely different pathways.
Clinical evidence base
Hepatitis B/C (approval-grade)
The trials in chronic hepatitis B underpin the Zadaxin approvals across 35+ countries, showing increased immune-activation markers and improved viral clearance versus controls. In hepatitis C, combination with interferon-based therapy improved viral response over interferon alone. These data formed the basis for the international approvals.
Sepsis
Tα1 has been studied in severe sepsis with reported effects on morbidity and mortality — one of the more clinically significant research strands, given sepsis's immune-dysregulation basis.
COVID-19 / respiratory (investigational)
It was studied during the pandemic for severe respiratory illness and lymphocyte restoration (e.g., NCT04487444 and related work). Results were variable across trials.
Honest caveat on breadth
The breadth of claimed indications — hepatitis, cancer adjunct, sepsis, COVID-19, vaccine response — from a single 28-amino-acid peptide raises the question of whether some effect sizes are inflated by study-design limitations. The most robust evidence supports immune modulation in immunocompromised patients.
Regulatory status
Approved as a pharmaceutical (Zadaxin / thymalfasin) in 35+ countries, but not FDA-approved in the United States. The absence of US approval despite 11,000+ subjects across 30+ trials reflects the specific regulatory pathways pursued and the indication scope, not a failed pivotal trial. Material supplied for laboratory work is research-use-only in the UK.
Evidence grade: Approved (ex-US). Among the strongest clinical evidence bases by volume of any compound in this library, tempered by the absence of FDA approval and questions about effect-size consistency across its many claimed indications.
See also
References
- 1
Dominari A, et al. Thymosin alpha 1: a comprehensive review of the literature World J Virol 2020.
- 2
Garaci E, et al. Thymosin α1 in combination therapies — hepatitis and cancer immunotherapy reviews Expert Opin Biol Ther 2015.
- 3
SciClone Pharmaceuticals Zadaxin (thymalfasin) prescribing and label documentation SciClone / Sigma-Tau regulatory documentation 2010.
- 4
ClinicalTrials.gov Thymalfasin (Tα1) for COVID-19 (NCT04487444) ClinicalTrials.gov 2020. https://clinicaltrials.gov/study/NCT04487444
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
